Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968602 · ClinicalTrials.gov registry record · Phase 4
Minocycline and Tobacco Craving in Smokers With Schizophrenia
A Phase 4 study of Schizophrenia and Tobacco Use, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02968602 is a Phase 4 study of Schizophrenia and Tobacco Use that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02968602, a Phase 4 study of Schizophrenia and Tobacco Use, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Craving for cigarettes is an important aspect that leads to challenges with smoking cessation. Persons with schizophrenia are more likely to smoke and to be heavier smokers than persons without schizophrenia, and may experience craving differently as well. Minocycline is an antibiotic medication that may impact craving. We will conduct a two-week randomized, double-blind, placebo-controlled, parallel group pilot study to investigate the effects of minocycline vs. placebo on craving and smoking behaviors in smokers with schizophrenia. Participants will take minocycline or matching placebo for two weeks. Participants will be assessed on aspects of craving and smoking behavior at baseline and after 1 and 2 weeks of minocycline or placebo treatment.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Minocycline
Study Locations (1)
Maryland
- Maryland Psyciatric Research Center - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2019-07-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968602
The ClinicalTrials.gov registry entry for NCT02968602 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (85% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02968602 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02968602 about?
NCT02968602 is a clinical study titled "Minocycline and Tobacco Craving in Smokers With Schizophrenia". Craving for cigarettes is an important aspect that leads to challenges with smoking cessation. Persons with schizophrenia are more likely to smoke and to be heavier smokers than persons without schizophrenia, and may experience craving differently as well. Minocycline is an antibiotic medication tha...
What is the current status of trial NCT02968602?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2017-03-31. Estimated completion is 2019-07-23.
What conditions does trial NCT02968602 study?
This clinical trial studies the following conditions: Schizophrenia, Tobacco Use.
What interventions are being tested in trial NCT02968602?
The interventions under investigation include: Placebo (OTHER), Minocycline (DRUG).
Who is sponsoring clinical trial NCT02968602?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968602 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.